

Detergent drags volumes; foods grow strongly...

HUL reported moderate 4% volume growth in Q3FY21 unlike strong growth for other FMCG companies mainly due to dismal sales in detergent category. The category (contributes ~30% to HUL's sales) has seen a muted sales growth post pandemic as schools & offices are not fully functioning. Further, price hikes in respect to cost inflation in palm oil & tea has been only calibrate & partial. The company has taken two subsequent price hikes of 2.5% in December 2020 & January 2021. Revenue grew by 20.9% to ₹ 11862 crore led by consolidation of acquired nutrition business (Horlicks, Boost). On a like to like basis, sales growth was 7%. Home care segment continue to post muted sales with 1.4% decline. Beauty & Personal care segment witnessed 9.7% revenue growth aided by price hikes taken in personal wash category. Foods category (like to like) witnessed a strong growth of 19% largely driven by price hike in tea & double digit growth in nutrition brands. The company has been able to maintain its gross margin (20 bps contraction) at 54% despite sharp increase (~40% in both) in tea & palm oil prices. It also maintained its advertisement spends at 11.7% which was in line with the sales growth however, overhead spends saw increase of 72 bps (% to sales) during the quarter. Operating profit increased by 16.7% to ₹2853 crore & operating margins contracted by 88 bps to ₹ 24.1%. Led by higher operating profit, net profit grew 18.8% to ₹ 1920 crore.

Nutrition business to drive food segment growth

The acquired nutrition brands Horlicks, Boost witnessed a double digit growth mainly driven by introduction of affordable pouch pack, national launch of Boost, new communication strategy & driving sachets in semi-urban & rural regions. Further, the company expect to get benefits of its large distribution network (2-3x of GSK existing network). It is also getting traction in chemist channel with the introduction of two new variants (Mother's Profit plus & Women Profit Plus). We believe the category would drive revenues and margins for the company.

Cost inflation, media spends to restrict margin expansion

Palm Oil & Tea prices have been up 40% compared to last year. Though, crude prices have been 30% lower, it is slowly inching up. The company has taken only partial price hikes in last six months. Further, media spends have increased by 175 bps sequentially due to aggressive new launches. We believe these cost increase would restrict operating margin expansion. We expect 70 bps operating margin expansion to 25.5% by FY23E.

Valuation & Outlook

Given the strong growth in nutrition business, judicious price hikes & expected revival in detergent business, we estimate 15.2% revenue growth in FY22E & further 7.8% growth in FY23E. We believe synergetic benefits of acquired nutrition brands would reflect in margin expansion going forward. The stock has seen a run-up recently. We change our recommendation from BUY to **HOLD** with a revised target price of ₹ 2600/share (earlier ₹ 2500).

Key Financial Summary

Key Financials	FY19	FY20	FY21E	FY22E	FY23E	CAGR (FY20-23E)
Total Operating Income	38734.0	38785.0	45997.4	52974.9	57132.0	21.4%
EBITDA	9147.0	9600.0	11313.7	13236.6	14597.0	23.3%
EBITDA Margin %	23.6	24.8	24.6	25.0	25.5	
Net Profit	6546.0	6738.0	7900.6	9510.2	10569.7	25.2%
EPS (₹)	30.31	31.19	33.63	40.48	44.99	
P/E	78.9	76.6	71.1	59.0	53.1	
RoNW %	87.6	85.7	19.1	22.5	24.3	
RoCE (%)	90.7	89.5	25.3	29.4	31.7	

Source: Company, ICICI Direct Research




Particulars

Particular (₹ crore)	Amount
Market Capitalization	561,506.6
Total Debt (FY20)	0.0
Cash and Investments (FY20)	6,265.0
EV	555,241.6
52 week H/L (₹)	2614 / 1756
Equity capital	234.9
Face value	₹ 1

Key Risk

- With the judicious price hikes, limited cost inflation & strong synergy benefits from acquired business, margin expansion can be larger than expected
- The dismal sales growth trend in detergent segment can remain prolonged & can impact overall growth for the company

Price Performance



Research Analyst

Sanjay Manyal
sanjay.manyal@icicisecurities.com

Exhibit 1: Variance Analysis

Particulars (₹ crore)	Q3FY21	Q3FY21E	Q3FY20	YoY (%)	Q2FY21	QoQ (%)	Comments
Net Sales	11,682.0	11,162.5	9,696.0	20.5	11,276.0	3.6	Net sales grew by 20.5% mainly on account of consolidation of acquired businesses. The Beauty & Personal care categories witnessed 9% & 19% led by price hikes taken in Soaps & Tea categories
Other Operating Income	180.0	159.8	112.0	60.7	166.0	8.4	
Raw Material Expenses	5,459.0	5,345.5	4,490.0	21.6	5,375.0	1.6	Despite, sharp rise (40%) increase in Palm Oil & Tea Prices, the company has been able to maintain gross margins
Employee Expenses	556.0	585.8	454.0	22.5	559.0	-0.5	
Marketing Expenses	1,388.0	1,133.3	1,163.0	19.3	1,139.0	21.9	Media spends increased sequentially with increased brand building amid new launches & ad-rates coming back to pre-covid levels
Other operating expenses	1,605.0	1,508.8	1,256.0	27.8	1,500.0	7.0	
EBITDA	2,853.2	2,748.8	2,445.0	16.7	2,868.2	-0.5	
EBITDA margin (%)	24.1	24.3	24.9	-88 bps	25.1	-101 bps	Operating margins contracted by 88 bps mainly on account of increased overhead spends given cost related to supply chain, distribution enhancement restored to pre-covid levels
Depreciation	272.0	244.4	232.0	17.2	249.0	9.2	
Interest	41.0	23.9	25.0	N.A.	29.0	N.A.	
Other Income	97.0	123.1	140.0	0.0	151.0	-35.8	
PBT	2,637.2	2,603.7	2,328.0	13.3	2,660.7	-0.9	
Exceptional Items	-42.0	0.0	-99.0	N.A.	-80.5	N.A.	
Tax Outgo	675.0	690.0	613.0	10.1	652.0	3.5	
PAT	1,920.2	1,913.7	1,616.0	18.8	2,008.7	-4.4	Net profit increased by 18.8% to ₹ 1920 crore
Key Metrics growth YoY (%)							
Home care	-1.4	3.0	9.8		-1.6		Home care segment saw muted growth mainly on account of subdued sales of detergent given offices, schools are still not fully operational
Beauty & Personal care	9.7	5.0	-2.8		-0.2		With the increase in soaps prices (2.5% in december) & higher tea prices, the segment saw strong 9.7% growth. The winter portfolio of skin care also saw strong growth
Food & Refreshments	79.9	48.0	7.9		82.9		Food business witnessed strong growth on the back of increase in tea prices & double digit growth in acquired nutrition business

Source: Company, ICICI Direct Research

Exhibit 2: Change in estimates

(₹ Crore)	FY21E			FY22E			FY23E			Comments
	Old	New	% Change	Old	New	% Change	Old	New	% Change	
Sales	42,606.0	45,317.7	6.4	48,908.9	52,115.0	6.6	52,744.4	56,204.6	6.6	We increase our revenue estimate largely on the back of price hikes taken in two major segments & strong growth in nutrition business
EBITDA	10,879.4	11,313.7	4.0	12,749.6	13,236.6	3.8	14,093.4	14,597.0	3.6	
EBITDA Margin (%)	25.2	24.6	-56 bps	25.6	25.0	-66 bps	26.7	26.0	-75 bps	With increase in media spends & raw material inflationary pressure, we change our margin estimates downwards
PAT	7,609.9	7,900.6	3.8	9,114.6	9,510.2	4.3	10,151.4	10,569.7	4.1	
EPS (₹)	32.4	33.6	3.8	38.8	40.5	4.3	43.2	45.0	4.1	

Source: Company, ICICI Direct Research

Exhibit 3: Assumptions


(₹ crore)	Current					Earlier			Comments
	FY19	FY20	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	
Home care	12,876.0	13,642.0	13,778.4	14,880.7	16,071.1	13,914.8	15,028.0	16,230.27	
Personal care	17,655.0	17,345.0	18,212.3	21,854.7	23,821.6	16,477.8	19,773.3	21,552.9	We change our estimate upwards due to price hikes taken by company
Food & Refreshments	7,133.0	7,450.0	12,441.5	14,432.1	15,298.1	11,547.5	13,395.1	14,198.8	In light of the price hike in tea & expected double digit growth in nutrition portfolio, we change our estimates upwards

Source: Company, ICICI Direct Research

Conference Call Highlights


- HUL reported 7% like to like growth with 4% volume growth in Q3FY21. Home care segment witnessed a sales decline of 1.4% given detergent segment is yet to witness revival from the pandemic impact. Given schools & offices are yet to fully functional, the category witness a slow & delayed recovery. Beauty & Personal care segment saw 9.7% growth during the quarter with winter portfolio saw strong growth & price hikes in soaps also aided the growth. Foods & refreshment category witness a 19% growth in Q3 led by price hike in tea segment & strong double digit growth in acquired nutrition business (Horlicks & Boost).
- The company has taken price hikes in tea category earlier mainly due to sharp rise in tea procurement prices. Further, Palm oil prices also witnessed cost inflation during the quarter. Both the commodities are higher by 40% YoY basis. Though, crude is down by 30% on YoY basis, it is gradually going up, which is likely to pressurise margins in medium term. The company has taken 2.5% price hike in soaps in December 2020 & subsequent 2.5% price hike in January 2021.
- Within Home care segment, household care (Vim, Domex) witnessed a double digit growth led by penetration gains. Detergent witnessed dismal numbers with still considerable lower out of home activity (Schools & Offices are yet to fully functional). Further, Purifiers saw better traction through e-commerce channel.
- The company launched range of disinfectant products under the Brand 'Nature Protect' in South India & through Ecommerce channel. It has also launched laundry sanitizers, disinfectant spray and wet wipes under Lifebuoy. Further in dish-wash category, it launched Vim-Matic dishwash. Fabric stain remover under Surf Excel brand.
- In Beauty & Personal care segment, the company has seen strong growth Lifebuoy, Dove, Peers aided by price hikes. Lux growth momentum also sustained during the quarter. Within Oral care segment, Close-up saw double digit growth whereas Pepsodent is yet see consumer traction. Skin Care segment (which is discretionary) saw pick-up in demand aided by winter product portfolio. Colour Cosmetics witnessed recovery with some pent up demand
- Foods & Refreshment segment saw strong double digit growth in Ketchups & Soups. Tea also grew in double digit with price hikes taken in previous quarters. Acquired Nutrition business also saw double digit growth with restoration of disrupted supply chain.
- The company launched Bru Veda in Coffee segment in South India. It also launched Kisaan Peanut Butter & Koor Chicken cube to leverage the trend of 'at-home' consumption
- Within Nutrition segment, the company re-launched Horlicks Mother's Plus & Women Plus in Q3. Further, the company has been leveraging its distribution network to grow these brands.
- Within the health, hygiene & Nutrition brands which contributes 80% of the company's portfolio saw 10% growth whereas discretionary brands which contributes 15% of the sales witnessed 1% decline (Q2 was 25% decline). The out of home brands contributes 5% of the sales still struggle to revive back of pre-covid levels with 15% decline in sales.
- The distribution reach have been restored fully to the pre-covid levels whereas SKUs has gone up by 10% compared to the pre-covid levels. Ecommerce sales has been up by 100% in Q3.

Sales growth on YoY basis (%)




Key Metrics

Exhibit 4: Home care revenue (₹ crore) and YoY growth (%)




Source: ICICI Direct Research, Company

Exhibit 5: Personal care revenue (₹ crore) & growth (%) trend




Source: ICICI Direct Research, Company

Exhibit 6: Foods & refreshment revenue (₹ crore) and growth (%) trend




Source: Company, ICICI Direct Research

Exhibit 7: EBITDA margin and raw material trend



Source: Company, ICICI Direct Research

Exhibit 8: PAT to grow at CAGR of 22.7% in FY20-23E



Source: Company, ICICI Direct Research

Exhibit 9: Valuation

	Sales	Growth	EPS	Growth	PE	EV/EBITDA	RoNW	RoCE
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)
FY20	38273.0	0.3	31.2	2.9	76.6	58.0	85.7	89.5
FY21E	45317.7	18.4	33.6	7.8	71.1	49.1	19.1	25.3
FY22E	52115.0	15.0	40.5	20.4	59.0	41.9	22.5	29.4
FY23E	56204.6	7.8	45.0	11.1	53.1	37.9	24.3	31.7

Source: Company, ICICI Direct Research

Financial summary

Exhibit 10: Profit and loss statement ₹ crore				
(Year-end March)	FY20	FY21E	FY22E	FY23E
Total operating Income	38,785.0	45,997.4	52,974.9	57,132.0
Growth (%)	0.1	18.6	15.2	7.8
Raw Material Expenses	17,793.0	21,360.4	24,155.9	25,561.2
Employee Expenses	1,691.0	2,220.6	2,605.8	2,810.2
Marketing Expenses	4,686.0	4,214.5	5,628.4	6,182.5
Administrative Expenses	2,047.0	2,537.8	2,918.4	3,259.9
Other expenses	2,968.0	4,350.5	4,429.8	4,721.2
Total Operating Expenditure	29,185.0	34,683.8	39,738.3	42,535.1
EBITDA	9,600.0	11,313.7	13,236.6	14,597.0
Growth (%)	5.0	17.9	17.0	10.3
Depreciation	938.0	1,012.5	966.2	992.2
Interest	106.0	137.8	130.9	117.8
Other Income	733.0	513.1	574.7	643.6
Exceptional Income	-197.0	0.0	0.0	0.0
PBT	9,092.0	10,676.5	12,714.2	14,130.6
Total Tax	2,354.0	2,775.9	3,204.0	3,560.9
PAT	6,738.0	7,900.6	9,510.2	10,569.7
Growth (%)	2.9	17.3	20.4	11.1
EPS (₹)	31.2	33.6	40.5	45.0

Source: Company, ICICI Direct Research

Exhibit 11: Cash flow statement ₹ crore				
(Year-end March)	FY20	FY21E	FY22E	FY23E
Profit after Tax	6,627.0	7,900.6	9,510.2	10,569.7
Add: Depreciation	938.0	1,012.5	966.2	992.2
(Inc)/dec in Current Assets	-34.0	-2,048.4	-1,626.4	-829.1
Inc/(dec) in CL and Provisions	331.0	-40.5	1,359.5	817.9
CF from operating activities	7,305.0	6,824.2	10,209.5	11,550.7
(Inc)/dec in Investments	2,249.0	-100.0	-100.0	-100.0
(Inc)/dec in loans & advances	-35.0	-25.0	-25.0	-25.0
(Inc)/dec in Fixed Assets	-713.0	313.0	-200.0	-1,192.2
Others	425.0	75.3	24.0	17.3
CF from investing activities	1926.0	263.3	-301.0	-1299.8
Issue/(Buy back) of Equity	0.0	18.9	0.0	0.0
Inc/(dec) in loan funds	-426.0	0.0	0.0	0.0
Dividend paid & dividend tax	-6,244.0	-6,343.4	-8,457.8	-9,397.6
Inc/(dec) in Sec. premium	0.0	0.0	0.0	0.0
Others	-6.0	0.0	0.0	0.0
CF from financing activities	-6,676.0	-6,324.4	-8,457.8	-9,397.6
Net Cash flow	2,555.0	763.1	1,450.6	853.2
Opening Cash	575.0	3,130.0	3,893.1	5,343.6
Closing Cash*	5,017.0	5,780.1	7,230.6	8,083.9

Source: Company, ICICI Direct Research *includes cash in bank

Exhibit 12: Balance sheet ₹ crore				
(Year-end March)	FY20	FY21E	FY22E	FY23E
Liabilities				
Equity Capital	216.0	234.9	234.9	234.9
Reserve and Surplus	7,815.0	41,053.2	42,105.6	43,277.7
Total Shareholders funds	8,031.0	41,288.2	42,340.6	43,512.7
Other Non Current Liabilities	1,269.0	1,269.0	1,269.0	1,269.0
Long Term Provisions	1198.0	118.5	142.7	158.5
Total Liabilities	10,498.0	42,675.7	43,752.2	44,940.2
Assets				
Gross Block	7,132.0	7,332.0	7,532.0	7,732.0
Less: Acc Depreciation	2,507.0	3,519.5	4,485.6	4,485.6
Net Block	4,625.0	3,812.5	3,046.4	3,246.4
Capital WIP	513.0	0.0	0.0	0.0
Total Fixed Assets	5,138.0	3,812.5	3,046.4	3,246.4
Goodwill on Consolidation	36	31717	31717	31717
Net Intangible Assets	395.0	395.0	395.0	395.0
Other Investments	252.0	352.0	452.0	552.0
Inventory	2,636.0	3,104.0	3,569.5	3,849.6
Debtors	1,046.0	1,862.4	1,856.2	2,001.8
Loans and Advances	0.0	248.3	285.6	308.0
Investments & Other CA	1,961.0	1,241.6	1,427.8	1,539.9
Cash	5,017.0	5,780.1	7,230.6	8,083.9
Total Current Assets	11,908.0	14,719.4	17,796.4	19,478.8
Creditors	7,399.0	7,449.5	8,566.9	9,239.1
Provisions & other CL	1,705.0	1,614.1	1,856.2	2,001.8
Total Current Liabilities	9,104.0	9,063.5	10,423.0	11,240.9
Net Current Assets	2,804.0	5,655.9	7,373.4	8,237.8
Others Non-Current Assets	717.0	742.0	767.0	792.0
Application of Funds	10,498.0	42,675.7	43,752.2	44,940.2

Source: Company, ICICI Direct Research

Exhibit 13: Key ratios ₹ crore				
(Year-end March)	FY20	FY21E	FY22E	FY23E
Per share data (₹)				
EPS	31.2	33.6	40.5	45.0
Cash EPS	35.5	37.9	44.6	49.2
BV	37.2	175.7	180.2	185.2
DPS	24.1	27.0	36.0	40.0
Cash Per Share	23.2	24.6	30.8	34.4
Operating Ratios (%)				
EBITDA/Total Operating Income	24.8	24.6	25.0	25.5
PBT Margin	23.9	23.2	24.0	24.7
PAT Margin	17.4	17.2	18.0	18.5
Inventory days	25	25	25	25
Debtor days	10	15	13	13
Creditor days	71	60	60	60
Return Ratios (%)				
RoE	85.7	19.1	22.5	24.3
RoCE	89.5	25.3	29.4	31.7
Valuation Ratios (x)				
P/E	76.6	71.1	59.0	53.1
EV / EBITDA	58.0	49.1	41.9	37.9
EV / Net Sales	14.5	12.3	10.6	9.8
Market Cap / Sales	14.7	12.4	10.8	10.0
Price to Book Value	64.3	13.6	13.3	12.9
Solvency Ratios				
Debt/EBITDA	0.0	0.0	0.0	0.0
Debt / Equity	0.0	0.0	0.0	0.0
Current Ratio	0.8	1.0	1.0	1.0
Quick Ratio	0.5	0.6	0.7	0.7

Source: Company, ICICI Direct Research

Exhibit 14: ICICI Direct coverage universe (FMCG)

	CMP	TP	Rating	M Cap	EPS (₹)			P/E (x)			Price/Sales (x)			RoCE (%)			RoE (%)		
	(₹)	(₹)		(₹ Cr)	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Colgate (COLPAL)	1,545	1,700	Buy	38,812	33.4	35.4	37.8	46.3	43.7	40.8	8.4	7.7	7.2	83.5	100.8	123.9	64.2	78.0	96.5
Dabur India (DABIND)	528	595	Buy	90,864	9.6	10.7	11.8	55.1	49.2	44.8	9.5	8.6	7.8	25.9	26.7	27.1	22.3	22.7	22.9
Hindustan Unilever (HINLEV)	2,390	2,600	Hold	561,507	33.6	40.5	45.0	71.1	59.0	53.1	12.4	10.8	10.0	25.3	29.4	31.7	19.1	22.5	24.3
ITC Limited (ITC)	211	225	Buy	213,884	11.2	12.0	13.4	18.8	17.5	15.7	4.7	4.2	3.8	27.2	30.5	35.7	20.9	23.4	27.5
Jyothy Lab (JYOLAB)	152	150	Hold	4,957	5.8	6.1	6.7	26.4	24.9	22.6	2.7	2.5	2.3	31.1	30.9	31.5	25.7	25.1	25.6
Marico (MARLIM)	412	440	Buy	46,834	8.8	9.5	9.9	46.9	43.3	41.8	6.2	5.6	5.4	42.3	45.1	46.0	36.3	38.5	39.3
Nestle (NESIND)	17,538	18,000	Hold	152,970	223.4	253.4	284.2	78.5	69.2	61.7	11.5	10.4	9.5	59.9	66.6	73.7	119.1	139.2	160.6
Tata Consumer Products (TATGLO)	573	605	Buy	52,158	12.0	13.5	15.1	47.7	42.4	37.9	4.8	4.4	4.1	9.8	10.5	11.1	7.8	8.6	9.3
VST Industries (VSTIND)	3,544	4,200	Hold	5,809	202.4	218.7	235.2	17.5	16.2	15.1	5.1	4.7	4.3	44.7	47.4	52.8	33.2	35.2	39.0
Varun Beverage (VARBEV)	901	730	Hold	19,429	11.3	21.7	26.6	79.6	41.5	33.9	3.0	2.5	2.3	12.3	18.6	20.7	10.1	16.7	17.6
Zydus Wellness (ZYDWEL)	1,935	2,300	Buy	11,359	27.8	65.7	71.7	69.7	29.4	27.0	6.1	5.4	5.0	6.9	8.3	8.9	5.9	8.6	9.2

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Sanjay Manyal, MBA (Finance) Research Analyst, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.